Cefoperazone pharmacokinetics and sputum levels after single/multiple i.m. injections in bronchopneumopathic patients and bone, pulmonary and prostatic tissue penetration.
Cefoperazone is a third-generation semisynthetic injectable cephalosporin. It has been reported that cefoperazone has beta-lactamase resistance and quite a broad antimicrobial spectrum against many Gram-positive and Gram-negative microorganisms and most anaerobes. In this study, the pharmacokinetics of cefoperazone were examined in a group of 10 patients suffering from acute exacerbations of chronic bronchitis, with purulent or mucopurulent expectorations. Cefoperazone was administered at the dose of 1 g i.m. every 12 hours. Serum and urinary parameters and the profile of bronchial mucus diffusion were assessed after the first administration and during the whole period of treatment which lasted for 7 days. In a second, third, and fourth group of volunteer patients who had to undergo surgical operations, bone, lung and prostatic penetration of cefoperazone was determined in correlation with serum levels.
D001842:Bone and Bones / Q000378:metabolism*; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism*; D002438:Cefoperazone / Q000378:metabolism*; D006801:Humans; D007273:Injections, Intramuscular; D007700:Kinetics; D008168:Lung / Q000378:metabolism*; D008297:Male; D011467:Prostate / Q000378:metabolism*; D013183:Sputum / Q000032:analysis*
D002438:Cefoperazone